Fradet Y - Search Results

1

The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index.

Allard P, Bernard P, Fradet Y, Têtu B. Allard P, et al. Among authors: fradet y. Br J Urol. 1998 May;81(5):692-8. doi: 10.1046/j.1464-410x.1998.00628.x. Br J Urol. 1998. PMID: 9634043

2

Markers of prognosis in superficial bladder cancer.

Fradet Y. Fradet Y. Semin Urol. 1992 Feb;10(1):28-38. Semin Urol. 1992. PMID: 1565901 Review. No abstract available.

3

Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Têtu B, Fradet Y, Candas B. Labrie F, et al. Among authors: fradet y. Cancer Surv. 1995;23:149-56. Cancer Surv. 1995. PMID: 7621455 Clinical Trial.

4

Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.

Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B, et al. Labrie F, et al. Among authors: fradet y. Clin Invest Med. 1993 Dec;16(6):499-509. Clin Invest Med. 1993. PMID: 8013155 Clinical Trial.

5

Critical appraisal of tumor markers in bladder cancer.

Fradet Y, Cordon-Cardo C. Fradet Y, et al. Semin Urol. 1993 Aug;11(3):145-53. Semin Urol. 1993. PMID: 8105526 Review. No abstract available.

6

Androgen receptor modulation in benign human prostatic tissue and prostatic adenocarcinoma during neoadjuvant endocrine combination therapy.

Van der Kwast TH, Têtu B, Fradet Y, Dupont A, Gomez J, Cusan L, Diamond P, Labrie F. Van der Kwast TH, et al. Among authors: fradet y. Prostate. 1996 Apr;28(4):227-31. doi: 10.1002/(SICI)1097-0045(199604)28:4<227::AID-PROS3>3.0.CO;2-A. Prostate. 1996. PMID: 8602398

7

Prevalence and clinical significance of HER/2neu, p53 and Rb expression in primary superficial bladder cancer.

Tetu B, Fradet Y, Allard P, Veilleux C, Roberge N, Bernard P. Tetu B, et al. Among authors: fradet y. J Urol. 1996 May;155(5):1784-8. J Urol. 1996. PMID: 8627884

8

Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer.

Têtu B, Allard P, Fradet Y, Roberge N, Bernard P. Têtu B, et al. Among authors: fradet y. Hum Pathol. 1996 Sep;27(9):922-6. doi: 10.1016/s0046-8177(96)90219-1. Hum Pathol. 1996. PMID: 8816887

9

Diagnostic accuracy of urinary cytology, and deoxyribonucleic acid flow cytometry and cytology on bladder washings during followup for bladder tumors.

Grégoire M, Fradet Y, Meyer F, Têtu B, Bois R, Bédard G, Charrois R, Naud A. Grégoire M, et al. Among authors: fradet y. J Urol. 1997 May;157(5):1660-4. J Urol. 1997. PMID: 9112500

10

Neoadjuvant hormonal therapy: the Canadian experience.

Labrie F, Cusan L, Gomez JL, Diamond P, Suburu R, Lemay M, Tetu B, Fradet Y, Bélanger A, Candas B. Labrie F, et al. Among authors: fradet y. Urology. 1997 Mar;49(3A Suppl):56-64. doi: 10.1016/s0090-4295(97)00170-2. Urology. 1997. PMID: 9123738 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

351 results

Search Page

Filters